Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Identifying HEREDITARY Prostate Cancer with Germline Genetic Testing

Identifying HEREDITARY Prostate Cancer with Germline Genetic Testing

Germ (sex-reproductive) cells are reproductive cells that enable gamete formation in sexually reproducing organisms. Germline tests are performed on noncancerous cells. The purpose of this test is to determine whether a person carries any "inherited" (rather than acquired) mutation and whether they are at risk of developing health problems such as cancer. Germline testing has become an important component of prostate cancer evaluation, management, and treatment. In patients at risk or in the presence of metastatic disease, finding a mutation in the relevant gene through germline testing is extremely important in selecting the most appropriate treatment method for the patient. To obtain the greatest possible benefit from this test, it is extremely important for physicians to closely follow developments in the field of genetics. A guideline was prepared to guide physicians in this field and make it easier to identify the tests that should be performed. In an interview on the important points physicians should know, Dr. Veda Giri answered questions.

Why Is a Guideline for Hereditary Genetic Testing in Prostate Cancer Needed?

Dr. Giri: “The use of germline tests for gene mutations that are inherited by the next generation and cause prostate cancer is increasing rapidly. Treatment options for metastatic prostate cancer are growing every day. For example, the United States Food and Drug Administration (FDA) recently approved two poly (ADO-ribose) polymerase (PARP) inhibitors, rucaparib and olaparib, for patients with metastatic prostate cancer that has progressed after initial treatment. The role of genetic information in diagnosing the disease at early stages is substantial and exciting. However, the growing group of men who need genetic testing and meet the criteria established for testing also brings some challenges. Issues such as increasing testing options, the difficulty physicians face in deciding whom to test, and increasing demand made it necessary to prepare this guideline and establish a framework.”

What Percentage of Men Harbor Germline Mutations for Prostate Cancer?

Dr. Giri: “Various studies have demonstrated many different and common mutations. Especially among men with metastatic disease, this proportion ranges from 12% to 17% in this population”.

Which Men Should Be Considered for Germline Prostate Cancer Genetic Testing?

Dr. Giri: “The strongest recommendations on which men should be considered for testing concern men with metastatic prostate cancer who are resistant or sensitive to hormone suppression therapy (castration) and have a family history of prostate cancer. Family history includes men with a brother, father, two or more male relatives diagnosed with prostate cancer at a young age (<60 years), or a relative who died of prostate cancer or metastatic prostate cancer. Other considerations for testing include T3a or more advanced prostate cancer, men with intraductal or ductal pathology, or men with stage 4 disease or a Gleason score of 8 or higher. Additional testing recommendations include a broader family history, including hereditary cancers or cancer-related syndromes such as hereditary breast or ovarian cancer and Lynch syndrome. A family member diagnosed with cancer at a young age (<50 years) warrants considering the person for germline testing. Genetic test results are also extremely important for identifying the right treatment as quickly as possible.”

Which Genes Have Priority for Testing?

Dr. Giri: “A total of 15 genes specific to hereditary prostate cancer have been identified, with an additional 80 genes identified in broader testing panels. The genes recommended for testing in metastatic cases are BRCA2, BRCA1 and DNA mismatch repair genes. People should also be tested for additional genes according to their family history and personal health history. In nonmetastatic cases, testing the BRCA2 gene is recommended; testing may begin with a small set of genes, and the number of genes tested may be increased according to the person's health history and family history. In men unaffected by cancer, genes to be tested include BRCA2 and HOXB13, with consideration of BRCA1, DNA mismatch repair genes, and the ATM gene. Again, testing in this group may begin with a small set of genes, with necessary genes added according to family history and personal health history.”

Which Recommendations Should Be Considered Based on Genetic Test Results?

Dr. Giri: “In people with metastatic prostate cancer, genetic test results are essential for identifying personalized targeted treatment methods. If the person has BRCA2 and BRCA1 gene mutations, these results guide the use of PARP inhibitor drugs. In particular, the recent approval of two PARP inhibitor drugs is promising. On the other hand, a mutation detected in DNA mismatch repair genes is important for providing information about the response to anti-PD-1 therapy. Close monitoring and early diagnosis efforts are recommended for men who carry a mutation but have not been diagnosed with prostate cancer. For men carrying a BRCA2 gene mutation, cancer screening in their 40s or starting screening 10 years before the age at which a family member was diagnosed with prostate cancer is strongly recommended. Similar recommendations are made for BRCA1, HOXB13, ATM, and MSH2, a DNA mismatch repair gene.”

What Should Be Done to Expand Prostate Cancer Genetic Testing?

Dr. Giri: “First, people working in this field should be enabled to access more comprehensive information on the subject. Public awareness of genetic testing should also be increased. For this purpose, informative content can be prepared online and made accessible to everyone." *

chronology of advanced prostate cancer treatments (1)chronology of advanced prostate cancer treatments (2)

Sources

Germlines 'Rich Source' of Prostate Cancer Info - Medscape - Jul 21, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Identifying HEREDITARY Prostate Cancer with Germline Genetic Testing

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy